Navigation Links
Kantar Health and ImpactRx Launch CancerMPact Monthly Drugs and Regimens for Oncology Business Decisions
Date:2/2/2010

NEW YORK and MOUNT LAUREL, N.J., Feb. 2 /PRNewswire/ -- Kantar Health, a leading healthcare-focused consultancy and oncology center of excellence, and ImpactRx, a pioneer in tracking and evaluating pharmaceutical promotion on the prescribing behavior of physicians, announced their partnership to introduce CancerMPact Monthly Drugs and Regimens, a timely, robust tool to assess oncology drug and regimen utilization.

Monthly Drugs and Regimens will complement Kantar Health's gold-standard CancerMPact Patient Metrics database to create a single, comprehensive source of oncology epidemiology disease and treatment information, projected from Active Disease patients, which are a true measure of market potential, providing critical information for all aspects of strategic planning, market analysis, and identification of commercial opportunities.  ImpactRx's ONCLink™ allows a statistically representative panel of oncologists to record their treatment decisions electronically immediately following a patient visit, ensuring precise and timely data.  In turn, Monthly Drugs and Regimens provides virtually real-time monthly updates of patient numbers on drug regimens and agents and the percentage of patients on specific regimens and agents, all by stage of disease and line of therapy.

The detailed data included in this new tool provides the granularity that will allow oncology marketers to:

  • Access current oncology drug and regimen use by tumor type, facilitating more accurate analysis and faster decision-making
  • Track oncology product commercialization and drug adoption by month
  • Better understand the patient populations for various tumor types by line of therapy
  • More accurately evaluate and forecast potential licensing or acquisition opportunities

"The addition of the Monthly Drugs and Regimens module to the CancerMPact product suite continues the strengthening evolution of Kantar Health oncology data," said David Robinson, Senior Director of Epidemiology of Kantar Health.  "From a single, integrated source, clients can access detailed information to fulfill critical data needs for strategic and practical market planning.  These include who's treated and who's not, and the specific drug regimen and/or agent, regardless of whether it's administered orally or intravenously."

"The combination of ImpactRx's proprietary network of high-value oncologists and Kantar Health's high-level cancer epidemiology data provides clients with unparalleled oncology treatment data breakdowns," said Jill Walton, Vice President and General Manager of Oncology, ImpactRx.  "This partnership offers the industry incomparable oncology expertise."

About Kantar Health

Kantar Health is a leading healthcare-focused global consultancy, specializing in portfolio optimization, market access, safety and outcomes, and brand and customer insights. Formed by uniting Consumer Health Sciences, MattsonJack, TNS Healthcare and Ziment, it is the next-generation decision support partner to the pharmaceutical and biotech industries, delivering evidence-based guidance to support clients' global and local success.

With 40+ offices throughout the Americas, Europe, Asia-Pacific, the Middle East and Africa, Kantar Health provides the broadest global footprint, coupled with the strongest local knowledge to help drive clients' maximum performance in every geography. Market-leading solutions ensure optimal decisions and actions across the brand life cycle, from assessing opportunities and sizing markets...to developing products and building access strategies...to positioning brands and creating messaging...to managing stakeholder relationships and monitoring treatment outcomes.

About ImpactRx

Founded in May 2000, ImpactRx's physician networks coupled with its custom research expertise support an unprecedented intelligence capability for the promotional initiatives of the pharmaceutical industry and for measuring their impact on physician behavior. Based in Mount Laurel, New Jersey, ImpactRx is a private company with investment financing provided by Mediphase Venture Partners (www.mediphaseventure.com), Oxford Bioscience Partners (www.oxbio.com), Merck Capital Ventures, and Omega Funds.

SOURCE Kantar Health

RELATED LINKS
http://www.kantarhealth.com

'/>"/>

SOURCE Kantar Health
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Tone Deafness Explained, from the Harvard Health Letter
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
8. ViroPharma to Present at Three Upcoming Healthcare Conferences
9. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
10. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... -- Research and Markets has announced the addition ... their offering. ... The report forecasts the global optical transceiver market to grow at ... The report covers the present scenario and the growth prospects of ... size, the report considers the revenue generated from the shipment of ...
(Date:12/9/2016)... , Dec. 9, 2016  RxWiki Inc., a ... and digital marketing strategies of thousands of pharmacies through ... won Austin Inno,s "50 on Fire" Award ... "We,re pleased to accept the award as one ... , Chief Executive Officer at RxWiki. "Our platform gives ...
(Date:12/8/2016)... 8, 2016 IRIDEX Corporation (NASDAQ: IRIX ... shares of common stock, $0.01 par value (the "Offering" with ... offering.  The final terms of the Offering will depend on ... there can be no assurance as to whether or when ... use the net proceeds it will receive from this offering ...
Breaking Medicine Technology:
(Date:12/9/2016)... New York, NY (PRWEB) , ... December 09, 2016 , ... ... that raises awareness for organ transplantation while encouraging readers to sign up as an ... for a lifesaving organ transplant. , An organ donor can save up to ...
(Date:12/9/2016)... ... 2016 , ... "I had a terrible time trying to get my grandson ... if the nebulizer had a more child-friendly design, then children would be more likely ... patent-pending NEBY to avoid the need to deliver medication via a nebulizer mask. The ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in ... and patient safety. Only a few hospitals and facilities have earned this distinction. ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... CURE Media ... centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat ... the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team ...
Breaking Medicine News(10 mins):